Where to allocate for dividends: Ausbil


The dividend outlook for Australian equities in FY23 is looking more challenged than before, according to Ausbil.
Dividends income had regained their losses since the COVID-19 pandemic but earnings growth was expected to be varied going forward as sectors adjusted to higher interest rates and stockmarket falls across developed markets.
The ASX 200 had lost 7.7% since the start of the year to 13 September while the S&P 500 had lost 14.3% over the same period.
It was therefore important to be invested in sectors that were less exposed to a potential slowdown and able to maintain their profit margins. This included companies in defensive sectors such as consumer staples, energy and quality growth businesses which were unaffected by the business cycle.
Michael Price, portfolio manager of the Ausbil Active Dividend Income fund, said: “We expect quite low growth in dividends [from the current high level] overall in FY23. Industrial companies and financial companies with pricing power and inelastic demand are likely to be able to increase their dividends.
“Resource dividends are likely to fall by 10% or more in FY23 [from elevated levels] based on current commodity forecasts, according to Ausbil analysis.
“Modest growth in dividends is expected from the banks, but this is dependent on interest rates increases not sending the Australian economy into recession.”
Recommended for you
The $673 billion global investment manager has appointed a former Zenith sales head as it seeks to expand its reach in the Australian wealth management market.
Fund managers may be operating in a squeezed environment, but a salary guide shows they are willing to pay up for specialist talent to diversify their fund range.
Reach Alternative Investments has entered into a strategic partnership with Russell Investments to bolster its wholesale private markets offering for financial advisers and investors.
Boutique investment consulting and research house Genium Investment Partners has announced a senior appointment to drive further growth in its research ratings business.